Skip to main content

CORRECTION article

Front. Immunol., 17 April 2019
Sec. Cancer Immunity and Immunotherapy
Volume 10 - 2019 | https://doi.org/10.3389/fimmu.2019.00780
This article is part of the Research Topic Cellular Therapies in Cancer View all 17 articles

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications

This article is a correction to:

  1. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications

    1. Read original article
\r\nHamid R. MirzaeiHamid R. Mirzaei1Analiz RodriguezAnaliz Rodriguez2Jennifer ShepphirdJennifer Shepphird3Christine E. BrownChristine E. Brown3Behnam Badie*Behnam Badie2*
  • 1Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • 2Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, CA, United States
  • 3Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute, Duarte, CA, United States

A Corrigendum on
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications

by Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., and Badie, B. (2017). Front. Immunol. 8:1850. doi: 10.3389/fimmu.2017.01850

In the original article, there was an error. We neglected to disclose a conflict of interest.

A correction has been made to the Conflict of Interest statement:

“Patents associated with CAR design, T cell manufacturing, and delivery have been licensed by Mustang Bio., Inc., for which CB and BB receive licensing and consulting payments.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: immunotherapy, T cell therapy, chimeric antigen receptor, CAR, solid tumors

Citation: Mirzaei HR, Rodriguez A, Shepphird J, Brown CE and Badie B (2019) Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Front. Immunol. 10:780. doi: 10.3389/fimmu.2019.00780

Received: 11 March 2019; Accepted: 25 March 2019;
Published: 17 April 2019.

Edited and reviewed by: Katy Rezvani, University of Texas MD Anderson Cancer Center, United States

Copyright © 2019 Mirzaei, Rodriguez, Shepphird, Brown and Badie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Behnam Badie, bbadie@coh.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.